274 related articles for article (PubMed ID: 32447129)
1. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
[TBL] [Abstract][Full Text] [Related]
2. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
3. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
4. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
[TBL] [Abstract][Full Text] [Related]
5. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
6. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
8. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
9. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
[TBL] [Abstract][Full Text] [Related]
11. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
12. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
13. Flexible care in breast cancer.
Wardley A; Canon JL; Elsten L; Peña Murillo C; Badovinac Crnjevic T; Fredriksson J; Piccart M
ESMO Open; 2021 Feb; 6(1):100007. PubMed ID: 33450658
[TBL] [Abstract][Full Text] [Related]
14. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
15. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
16. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.
Schneider PP; Ramaekers BL; Pouwels X; Geurts S; Ibragimova K; de Boer M; Vriens B; van de Wouw Y; den Boer M; Pepels M; Tjan-Heijnen V; Joore M
Value Health; 2021 May; 24(5):668-675. PubMed ID: 33933235
[TBL] [Abstract][Full Text] [Related]
17. Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
Mankinen P; Vihervaara V; Torvinen S; Martikainen J; Soini E
J Med Econ; 2019 Apr; 22(4):328-335. PubMed ID: 30644325
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
20. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]